Secondary Acute Myeloid Leukemia — Trials

Secondary Acute Myeloid Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

212 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 21
Ph III recruiting: 0
Growth YoY: —
Industry share: 7%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (39)

clinicaltrialsPublishedShowing 51–56 of 56 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00602771	Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia	completed	Phase 2	84	National Cancer Institute (NCI)NIH	1	Oct 9, 2014	clinicaltrials
NCT00096122	Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia	completed	Phase 1 / Phase 2	95	National Cancer Institute (NCI)NIH	1	May 26, 2014